Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Hoffmann-La Roche Inc. v. Apotex Inc.
Case Number:
13-1128
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
April 11, 2014
Roche's Boniva Patents Are Obvious, Fed. Circ. Affirms
The Federal Circuit on Friday upheld a lower court's decision invalidating two patents owned by Hoffmann-La Roche Inc. for the osteoporosis drug Boniva, ruling that they would be obvious in view of prior art in a victory for several generics makers.
-
December 06, 2013
Roche Asks Fed. Circ. To Revive Boniva Dosage Patents
Hoffmann-La Roche Inc. pushed a Federal Circuit panel on Friday to resurrect two of its patents covering the osteoporosis drug Boniva despite protests from several generic-drug makers, maintaining there was nothing in the record to support the lower court's obviousness finding.